Asset

  • No.

    131

  • Asset Title

    ‘Off-the-Shelf’ CMV EphA3 CAR T Cell Therapy for Solid Tumours

  • Organization

    QIMR

  • Product Type

    Cell therapy

  • Therapeutic Area

    Oncology

  • Development Stage

    Phase 1

  • Technical Summary

    • Adoptive T cell therapy is a promising treatment option for solid tumours but faces numerous obstacles.

    • There are 3 components to QIMR’s novel T cell therapy.

    • QIMR developed a CMV-specific T-cell therapy for the treatment of solid tumours and transplant indications.

    • QIMR completed 3 clinical trials using CMV immunotherapy in GBM and transplant patients with promising results.

    • The CMV T cell therapy improved survival in primary GBM patients treated prior to progression.

    • The CMV T cells can be used as a safe and effective delivery platform for adoptive immunotherapy.

  • Patent

    US20200316119A1

  • Publication

  • Attachment

TOP